skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Brentuximab Vedotin (Code C66944)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Brentuximab Vedotin

Definition: An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.

Display Name: Brentuximab Vedotin

Label: Brentuximab Vedotin

NCI Thesaurus Code: C66944 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2932409  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-CD30 Antibody-Drug Conjugate SGN-35
Anti-CD30 Monoclonal Antibody-MMAE SGN-35
Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35
Brentuximab Vedotin

External Source Codes: 
CAS Registry Number 914088-09-8 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 530758
PDQ Open Trial Search ID 530758 (check for NCI PDQ open clinical trial info)
UMLS CUI C2932409

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Hodgkin lymphoma; anaplastic large cell lymphoma (ALCL)
Chemical_Formula C68H106N11O15S
code C66944
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name SGN-35
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom